12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioTime, Reproductive Genetics Institute deal

BioTime will use its ACTCellerate technology to differentiate human embryonic stem cell (hESC) lines from the institute...

Read the full 65 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >